The Protocol Specific Research Support (PSRS) provides funding for innovative, short term, feasibility and phase I clinical trials originating from scientific investigators within KCI. The primary objective is to foster investigator-initiated trials that bring new results from the basic science laboratories to KCI's clinics. PSRS provides funding to encourage expansion of the number of investigator-initiated protocols and the development of innovative trials that may have insufficient preliminary data to be competifive for peer reviewed funding. The Clinical Research Coordinator (CRC) and Business Analyst funded by PSRS provide data management and study coordination in support of high priority, innovative, feasibility and phase I invesfigator-inifiated clinical research protocols. The services provided by the CRC are in accordance with the services of the Clinical Trials Office Core (Secfion 9.1.10). The Business Analyst creates protocol specific calendars and electronic case report forms (eCRFs) within OnCore?. The information captured in the eCRF is used by the Biostatistics Core for protocol data analysis.
The purpose of PSRS is to provide data management support for innovative, short term, feasibility and phase I clinical trials originating from scientific investigators within KCI. The primary objective is to foster investigator-initiated trials that bring new results from the basic science laboratories to the KCI clinics.
|Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164|
|Eggly, Susan; Hamel, Lauren M; Foster, Tanina S et al. (2017) Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. Patient Educ Couns 100:818-826|
|Bao, Bin; Mitrea, Cristina; Wijesinghe, Priyanga et al. (2017) Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep 7:44125|
|Bernardo, Margarida M; Dzinic, Sijana H; Matta, Maria J et al. (2017) The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. J Cell Biochem 118:1639-1647|
|Soave, Claire L; Guerin, Tracey; Liu, Jinbao et al. (2017) Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev 36:717-736|
|Jones, Carissa C; Bush, William S; Crawford, Dana C et al. (2017) Germline Genetic Variants and Lung Cancer Survival in African Americans. Cancer Epidemiol Biomarkers Prev 26:1288-1295|
|Bosnyák, Edit; Michelhaugh, Sharon K; Klinger, Neil V et al. (2017) Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. Clin Nucl Med 42:341-347|
|Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323|
|Tan, Zhijing; Nie, Song; McDermott, Sean P et al. (2017) Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. J Proteome Res 16:842-851|
|Embogama, D Maheeka; Pflum, Mary Kay H (2017) K-BILDS: A Kinase Substrate Discovery Tool. Chembiochem 18:136-141|
Showing the most recent 10 out of 726 publications